NCT00959218 - Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

April 30, 2010

Conditions

Central Neuropathic Pain in Multiple Sclerosis

Interventions

DRUG

Dronabinol

oral solution, daily dose up to 15 mg, treatment up to 2.5 years

DRUG

Placebo

oral solution

Trial Locations (1)

Maerkische Kliniken GmbH, Klinikum Luedenscheid, Akademisches Lehrkrankenhaus der Universitaet Bonn, Klinik fuer Neurologie, Lüdenscheid